Agents and Actions

, Volume 24, Issue 3–4, pp 387–394 | Cite as

Effects of antirheumatic drugs on leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytesin vitro

  • E. Moilanen
  • J. Alanko
  • E. Seppälä
  • H. Vapaatalo


The effects ofd-penicillamine, sodium aurothiomalate, indomethacin, timegadine and tolfenamic acid on the lipoxygenase and cyclo-oxygenase pathways of arachidonic acid metabolism were studied in human polymorphonuclear leukocytes (PMNs)in vitro. In short-term incubations,d-penicillamine and aurothiomalate did not affect leukotriene B4 (LTB4), prostaglandin E2 (PGE2) or thromboxane B2 (TXB2) production. Each of the three non-steroidal anti-inflammatory drugs (NSAIDs) used were potent inhibitors of prostanoid synthesis. In higher concentrations they also reduced LTB4 production; timegadine and tolfenamic acid were effective in concentrations comparable to those measured in plasma during drug therapy, whereas indomethacin was needed in ten times higher concentrations. The different effects of NSAIDs on 5-lipoxygenase activity may be of importance in their therapeutic actions as well as in the appearance of some side-effects, e.g. gastric irritation and “aspirin-induced” asthma.


Arachidonic Acid Indomethacin PGE2 Thromboxane LTB4 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    L. E. Trang,Prostaglandins and inflammation. Semin. Arthritis Rheum.9, 153–190 (1980).CrossRefPubMedGoogle Scholar
  2. [2]
    L. B. Klickstein, C. Shapleigh and E. J. Goetzl,Lipoxygenation of arachidonic acid as a source of polymorphonuclear chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondylarthritis. J. clin. Invest.66, 1166–1170 (1980).PubMedGoogle Scholar
  3. [3]
    E. M. Davidson, S. A. Rae and M. J. H. Smith,Leukotriene B 4,a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann. rheum. Dis.42, 677–679 (1983).PubMedGoogle Scholar
  4. [4]
    S. M. Krane,Mechanisms of tissue destruction in rheumatoid arthritis. In:Arthritis and allied conditions, pp 593–604 (Ed. D. J. McCarty). Lea & Febiger, Philadelphia 1985.Google Scholar
  5. [5]
    G. P. Lewis,Immunoregulatory activity of metabolites of arachidonic acid and their role in inflammation. Br. med. Bull.39, 243–248 (1983).PubMedGoogle Scholar
  6. [6]
    G. A. Higgs, S. Moncada and J. R. Vane,Eicosanoids in inflammation. Ann. clin. Res.16, 287–299 (1984).PubMedGoogle Scholar
  7. [7]
    P. Sirois,Pharmacology of the leukotrienes. Adv. Lipid Res.21, 79–101 (1985).PubMedGoogle Scholar
  8. [8]
    M. A. Bray,Leukotrienes in inflammation. Agents and Actions19, 87–99 (1986).CrossRefPubMedGoogle Scholar
  9. [9]
    G. A. Higgs, S. Moncada, J. A. Salmon and K. Seager,The source of thromboxane and prostaglandins in experimental inflammation. Br. J. Pharmacol.79, 863–868 (1983).PubMedGoogle Scholar
  10. [10]
    P. M. Simmons, J. A. Salmon and S. Moncada,The release of leukotriene B 4 during experimental inflammation. Biochem. Pharmacol.32, 1353–1359 (1983).CrossRefPubMedGoogle Scholar
  11. [11]
    J. R. Vane,Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol.231, 232–235 (1971).PubMedGoogle Scholar
  12. [12]
    S. H. Ferreira, S. Moncada and J. R. Vane,Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol.231, 237–239 (1971).CrossRefPubMedGoogle Scholar
  13. [13]
    J. B. Smith and A. L. Willis,Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol.231, 235–237 (1971).PubMedGoogle Scholar
  14. [14]
    H. O. J. Collier,Prostaglandins and aspirin. Nature New Biol.232, 17–19 (1971).CrossRefGoogle Scholar
  15. [15]
    G. A. Higgs and J. R. Vane,Inhibition of cyclo-oxygenase and lipoxygenase. Br. med. Bull.39, 265–270 (1983).PubMedGoogle Scholar
  16. [16]
    I. L. Bonta and M. J. Parnham,Prostaglandins and chronic inflammation. Biochem. Pharmacol.27, 1611–1623 (1978).CrossRefPubMedGoogle Scholar
  17. [17]
    S. Abramson, H. Korchak, R. Ludewig, H. Edelson, K. Haines, R. I. Levin, R. Herman, L. Rider, S. Kimmel and G. Weissmann,Modes of action of aspirin-like drugs. Proc. natn. Acad. Sci. USA82, 7227–7231 (1985).Google Scholar
  18. [18]
    E. Moilanen, E. Seppälä, M. Nissilä and H. Vapaatalo,d-penicillamine effects on prostanoid production in adherent rheumatic synovial cells in primary culture. Prostaglandins Leukotrienes Med.28, 141–152 (1987).CrossRefGoogle Scholar
  19. [19]
    A. Bøyum,Isolation of lymphocytes, granulocytes and macrophages. Scand. J. Immunology Suppl.5, 9–15 (1976).Google Scholar
  20. [20]
    S. Shak and I. M. Goldstein,The major pathway for leukotriene B 4 catabolism in human polymorphonuclear leukocytes involves ω-oxidation by a cytochrome P-450 enzyme. In:Prostaglandins, Leukotrienes and Lipoxins. pp 97–109 (Ed. J. M. Bailey). Plenum Press, New York 1985.Google Scholar
  21. [21]
    S. A. Metz, M. E. Hall, T. W. Harper and R. C. Murphy,Rapid extraction of leukotrienes from biological fluids and quantitation of high-performance liquid chromatography. J. Chromatogr.233, 193–201 (1982).PubMedGoogle Scholar
  22. [22]
    J. A. Salmon, P. M. Simmons and R. M. J. Palmer,A radio-immunoassay for leukotriene B 4. Prostaglandins24, 225–235 (1982).CrossRefPubMedGoogle Scholar
  23. [23]
    E. Seppälä, O. Pora and T. Metsä-Ketelä,A modified method for extraction and purification of prostaglandins with resin XAD-2. Prostaglandins Leukotrienes Med. 14, 235–241 (1984).CrossRefGoogle Scholar
  24. [24]
    S. Inayama, H. Hori, T. Shibata, Y. Ozawa, K. Yamagami, M. Imazu and H. Hayashida,Simple and rapid separation of certain prostaglandins by reversed-phase high-performance liquid chromatography. J. Chromatogr.194, 85–88 (1980).CrossRefGoogle Scholar
  25. [25]
    P. J. Pentikäinen, P. J. Neuvonen and C. Backman,Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur. J. clin. Pharmacol.19, 359–365 (1981).CrossRefPubMedGoogle Scholar
  26. [26]
    S. G. K. Dauwe, A. McBurney and J. Ward,The influence of food intake on the bioavailability of timegadine, a novel non-steroidal anti-inflammatory drug. Br. J. clin. Pharmacol.15, 495–498 (1983).PubMedGoogle Scholar
  27. [27]
    G. Alván, M. Orme, L. Bertilsson, R. Ekstrand and L. Palmér,Pharmacokinetics of indomethacin. Clin. Pharmacol. Ther.18, 364–373 (1975).PubMedGoogle Scholar
  28. [28]
    B. J. R. Whittle, N. Oren-Wolman and P. H. Guth,Gastric vasoconstrictor actions of leukotriene C 4,PGF and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am. J. Physiol.248, G580-G586 (1985).PubMedGoogle Scholar
  29. [29]
    B. M. Peskar, K. Lange, U. Hoppe and B. A. Peskar,Ethanol stimulates formation of leukotriene C 4 in rat gastric mucosa. Prostaglandins31, 283–293 (1986).CrossRefPubMedGoogle Scholar
  30. [30]
    C. K. Axelsson, L. V. Christiansen, A. A. Johansen and P. E. Poulsen,Comparative effects of tolfenamic acid and acetylsalicylic acid on human gastric mucosa. Scand. J. Rheumatol.6, 23–27 (1977).PubMedGoogle Scholar
  31. [31]
    V. Rejholec, H. Vapaatalo, O. Tokola and G. Gothoni,Tolfenamic acid in ankylosing spondylarthritis: A doubleblind comparison to indomethacin. Scand. J. Rheumatol. Suppl.36, 3–7 (1980).Google Scholar
  32. [32]
    C. W. Parker, B. A. Jakschik, M. G. Huber and S. F. Falkenhein,Characterization of slow reacting substance as a family of thiolipids derived from arachidonic acid. Biochem. biophys. Res. Commun.89, 1186–1192 (1979).CrossRefPubMedGoogle Scholar
  33. [33]
    J. E. Parente, K. Wong, P. Davis, J. F. Burka and J. S. Percy,Effects of gold compounds on leukotriene B 4,leukotriene C 4 and prostaglandin E 2 production by polymorphonuclear leukocytes. J. Rheumatol.13, 47–51 (1986).PubMedGoogle Scholar
  34. [34]
    F. Capasso, I. A. Tavares, R. Tsang and A. Bennett,Effects of d-penicillamine, levamisole and tiopronin on eicosanoid synthesis by rat gut tissue. Agents and Actions17, 395–396 (1986).CrossRefPubMedGoogle Scholar
  35. [35]
    H. Vapaatalo, J. Parantainen and I.-B. Lindén,Modulation of prostaglandin biosynthesis by d-penicillamine and gold derivatives. In:Prostanoids, pp. 27–36 (Ed. V. Kecskeméti). Pergamon Press, Oxford 1980.Google Scholar
  36. [36]
    P. Borgeat, M. Nadeau, H. Salari, P. Poubelle and B. Fruteau de Laclos,Leukotrienes: Biosynthesis, metabolism and analysis. Adv. Lipid Res.21, 47–77 (1985).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • E. Moilanen
    • 1
  • J. Alanko
    • 1
  • E. Seppälä
    • 1
  • H. Vapaatalo
    • 1
  1. 1.Department of Biomedical SciencesUniversity of TampereTampereFinland

Personalised recommendations